{"gene":"SDC1","run_date":"2026-06-10T07:46:30","timeline":{"discoveries":[{"year":1997,"finding":"Syndecan-1 core protein directly mediates internalization of lipoprotein lipase-enriched lipoproteins via a pathway distinct from clathrin-coated pits; the internalization requires microfilaments (cytochalasin B-sensitive) and tyrosine kinase activity (genistein-sensitive), and is triggered by ligand clustering of the transmembrane/cytoplasmic domain.","method":"CHO cell transfection with syndecan-1 expression vector; chimeric FcR-Synd1 construct; internalization kinetics and pharmacological inhibitors (cytochalasin B, genistein)","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1/2 / Strong — chimeric construct reconstitution, multiple pharmacological dissections, kinetic comparisons with coated-pit pathway in a single rigorous study","pmids":["9294130"],"is_preprint":false},{"year":2000,"finding":"Syndecan-1 (and syndecan-4) mediate invasion of OpaHSPG-expressing Neisseria gonorrhoeae into epithelial cells; the intracellular domains of both syndecans are required for bacterial uptake, as dominant-negative truncation mutants lacking the cytoplasmic tail abolish invasion. Syndecan-4 mutants lacking the PKC/PIP2-binding dimerization motif or the C-terminal EFYA motif (which binds syntenin/CASK) also lose invasion capacity.","method":"HeLa cell overexpression of wild-type and cytoplasmic-deletion/point-mutant syndecan-1 and -4 constructs; bacterial invasion assay; co-localization by microscopy","journal":"Cellular microbiology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — structure-function mutagenesis with multiple mutant constructs and functional invasion readout in a single focused study","pmids":["11207564"],"is_preprint":false},{"year":2003,"finding":"RANTES/CCL5 specifically binds to syndecan-1 and syndecan-4 (but not syndecan-2) on human monocyte-derived macrophages; this binding is dependent on the glycosaminoglycan chains and facilitates subsequent interaction of RANTES with the GPCR CCR5.","method":"Co-immunoprecipitation; glycosaminidase pre-treatment of cells; binding inhibition assays","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — co-IP with enzymatic chain-removal confirmation, single lab, two orthogonal methods","pmids":["14637022"],"is_preprint":false},{"year":2008,"finding":"Membrane-bound syndecan-1 promotes MCF-7 cell proliferation and inhibits invasiveness, whereas constitutively shed (soluble) syndecan-1 decreases proliferation and promotes invasion into Matrigel; FGF-2-mediated MAPK signaling is reduced by siRNA knockdown of syndecan-1. Soluble SDC1 downregulates TIMP-1 and E-cadherin, accounting for the pro-invasive switch.","method":"Stable transfection of wild-type, constitutively shed, and uncleavable SDC1 constructs in MCF-7; siRNA knockdown; Matrigel invasion; Western blot for MAPK signaling; Affymetrix microarray","journal":"Carcinogenesis","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple construct types (WT/shed/uncleavable), siRNA, functional invasion and signaling readouts, single lab with orthogonal methods","pmids":["19126645"],"is_preprint":false},{"year":2009,"finding":"Syndecan-1 acts as a co-adhesion receptor for Type I collagen (alongside α2β1 integrin) in squamous cell carcinoma cells; siRNA-mediated depletion of Sdc1 reduces adhesion to collagen I, abolishes adhesion-induced RhoA activation, strongly activates Rac1, reduces focal adhesion plaque formation, and enhances cell spreading and motility specifically on collagen I substrates.","method":"siRNA knockdown; adhesion assays; RhoA/Rac1 activation assays; focal adhesion staining; cell motility on various ECM substrates","journal":"Experimental cell research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — specific siRNA KD with multiple orthogonal functional and signaling readouts, single lab","pmids":["20036233"],"is_preprint":false},{"year":2009,"finding":"Syndecan-1 and syndecan-4 are required for RANTES/CCL5-induced migration and invasion of human hepatoma cells; siRNA knockdown of SDC1 or SDC4 reduces cell chemotaxis and spreading induced by RANTES/CCL5; the chemokine effect depends on FAK phosphorylation, PI3K, MAPK, and Rho kinase activation.","method":"siRNA knockdown of SDC1 and SDC4; pharmacological inhibitors; Boyden chamber migration/invasion assay; Western blot for FAK phosphorylation","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA KD of two specific syndecans with functional migration readout and signaling pathway dissection, single lab","pmids":["19632304"],"is_preprint":false},{"year":2010,"finding":"Syndecan-1 and syndecan-2 gene silencing by RNA interference reduces HSV-1 entry and plaque formation in host cells; conversely, HSV-1 infection increases syndecan-1 and syndecan-2 protein synthesis and surface heparan sulfate expression.","method":"siRNA knockdown of syndecan-1 and syndecan-2; viral entry and plaque formation assays; flow cytometry","journal":"The Journal of general virology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — specific siRNA KD with viral entry and plaque readouts, single lab, single method type","pmids":["21148276"],"is_preprint":false},{"year":2012,"finding":"Syndecan-1 overexpression in HT-1080 fibrosarcoma cells promotes proliferation and chemotaxis via upregulation of syndecan-2; the pro-migratory effect of syndecan-1 is abolished when syndecan-2 is silenced. The ectodomain of syndecan-1 is dispensable for cytoplasmic-domain-mediated proliferative effects in vitro. Syndecan-1 overexpression activates IGF1R and increases Ets-1 expression.","method":"Transfection of full-length and truncated syndecan-1 constructs; syndecan-2 antisense silencing; in vitro proliferation, migration, invasion assays; Western blot for IGF1R and Ets-1; in vivo xenograft","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple construct types plus silencing rescue experiments with orthogonal readouts, single lab","pmids":["22745764"],"is_preprint":false},{"year":2015,"finding":"Heparanase stimulates the exosomal secretion of syntenin-1, syndecan and CD63 in a concentration-dependent and syntenin-1/ALIX-dependent manner by trimming the heparan sulfate chains on syndecans; syndecans (but not glypicans) support exosome biogenesis in heparanase-exposed cells. Heparanase stimulates intraluminal budding of syndecan and syntenin-1 in endosomes, dependent on the syntenin-ALIX interaction.","method":"Overexpression/knockdown of heparanase and syntenin-1/ALIX in cell lines; exosome fractionation and Western blot; electron microscopy of endosomal membranes; glypican vs syndecan comparison","journal":"Cell research","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal gain-and-loss-of-function, multiple orthogonal methods (biochemical fractionation, EM), replicated across multiple cargo and receptor types in one rigorous study","pmids":["25732677"],"is_preprint":false},{"year":2015,"finding":"Syndecan-1 binds IL-34 via its chondroitin sulfate chains and modulates IL-34-induced M-CSFR signaling; syndecan-1 overexpression or a blocking anti-syndecan antibody alters M-CSFR phosphorylation patterns. IL-34-induced migration of myeloid cells (THP-1, M2a macrophages) is syndecan-1 dependent.","method":"Scatchard and binding inhibition assays with 125I-radiolabelled cytokines; surface plasmon resonance; chondroitinase treatment; syndecan-1 overexpression and siRNA; Western blot for M-CSFR phosphorylation; migration assays with blocking antibody","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — direct binding assays (SPR, radiolabel), enzymatic chain removal, overexpression/silencing, and functional migration readout in one study","pmids":["25662098"],"is_preprint":false},{"year":2016,"finding":"Syndecan-1 (CD138) captures IGF1 receptor (IGF1R) on multiple myeloma cell surfaces, maintaining constitutive and ligand-induced IGF1R kinase activity that phosphorylates and inhibits ASK1 (at Tyr and Ser83/Ser966), thereby suppressing ASK1-dependent, JNK/caspase-3-mediated apoptosis. A peptide inhibitor (SSTNIGF1R) that blocks IGF1R capture by SDC1 restores ASK1 activity and triggers apoptosis.","method":"Co-immunoprecipitation of SDC1 and IGF1R; peptide inhibitor (SSTNIGF1R) blocking assay; Western blot for IGF1R kinase activity, ASK1 phosphorylation; apoptosis assays; in vivo xenograft tumor model","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — co-IP, peptide-based mechanistic rescue, phospho-specific signaling analysis, and in vivo validation in one study","pmids":["27364558"],"is_preprint":false},{"year":2014,"finding":"Syndecan-1 deficiency (Sdc-1−/− mice) causes impaired macrophage migration and enhanced adhesion in M2 macrophages; Sdc-1−/− macrophages show delayed lymphatic clearance in thioglycollate-induced peritonitis and greater atherosclerotic plaque burden in ApoE−/−Sdc-1−/− mice on Western diet.","method":"Sdc-1 null mouse model; in vitro migration and adhesion assays; in vivo thioglycollate peritonitis model; ApoE/Sdc-1 double knockout atherosclerosis model","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic KO with defined cellular phenotype (migration/adhesion), in vivo disease model confirmation, single lab with multiple orthogonal readouts","pmids":["25550207"],"is_preprint":false},{"year":2019,"finding":"Dynamic endocytic recycling of CD138/syndecan-1 surface expression in myeloma cells regulates a switch between high-proliferation/low-motility (CD138-high) and low-proliferation/high-motility (CD138-negative) states; neutralizing CD138 rapidly triggers migration and intravasation in vivo, leading to increased bone dissemination. CD138-high myeloma cells show enhanced IL-6R signaling and superior engraftment.","method":"In vivo Vk*MYC murine myeloma model; flow cytometry; in vivo motility imaging; endocytosis trafficking assays; CD138-neutralizing antibody; bortezomib combination treatment","journal":"Leukemia","confidence":"High","confidence_rationale":"Tier 2 / Moderate — in vivo genetic/antibody model with defined cellular phenotypes and mechanistic endocytic trafficking experiments, multiple orthogonal readouts","pmids":["31439945"],"is_preprint":false},{"year":2022,"finding":"After irradiation, SDC1 binds TGM2 and transports it from the cell membrane to lysosomes; TGM2 then binds LC3 on autophagosomes via LC3-interacting regions (LIRs) to coordinate autophagosome-lysosome fusion, enabling EPG5 to stabilize the STX17-SNAP29-VAMP8 SNARE complex. SDC1-TGM2 interaction is required for autophagic flux and radioresistance in glioblastoma.","method":"Co-immunoprecipitation; confocal microscopy (mRFP-GFP-LC3 flux reporter); transmission electron microscopy; Western blot; SDC1/TGM2 knockdown; TGM2 inhibitor (cystamine) in vivo mouse GBM model","journal":"Autophagy","confidence":"High","confidence_rationale":"Tier 2 / Moderate — co-IP protein complex, live-cell autophagic flux imaging, EM, and in vivo pharmacological validation in one study","pmids":["35913916"],"is_preprint":false},{"year":2023,"finding":"SDC1 forms a complex with TGM2, FLOT1, and BHMT to maintain autophagic flux: after irradiation SDC1 carries TGM2 from the cell membrane into cytoplasm and to lysosomes via FLOT1; TGM2 then recognizes BHMT on autophagosomes to coordinate autophagosome-lysosome encounter. This SDC1-TGM2-FLOT1-BHMT complex promotes GBM radioresistance.","method":"Co-IP assays; colony formation; flow cytometry; qPCR; Western blot; mRFP-GFP-LC3; transmission electron microscopy; immunofluorescence","journal":"Theranostics","confidence":"High","confidence_rationale":"Tier 2 / Moderate — co-IP defining a four-protein complex, multiple orthogonal cellular and structural methods, functionally linked to radioresistance phenotype","pmids":["37441590"],"is_preprint":false},{"year":2009,"finding":"Syndecan-1 knockdown in urothelial carcinoma cells (siRNA) downregulates transcription factor JunB and the long isoform of FLIP (FLIP-L), leading to pan-caspase-inhibitor-sensitive apoptosis. In vivo transurethral siRNA injection reduces SDC1 expression and tumor growth in an orthotopic mouse bladder cancer model.","method":"siRNA transfection; Western blot for JunB and FLIP-L; apoptosis assays with pan-caspase inhibitor; orthotopic mouse bladder cancer model","journal":"Cancer science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA KD with defined apoptotic pathway placement (JunB/FLIP-L) and in vivo confirmation, single lab","pmids":["19860843"],"is_preprint":false},{"year":2008,"finding":"Syndecan-1 and syndecan-2 have opposing roles in PEI-mediated gene delivery: SDC1 overexpression enhances transfection efficiency, while SDC2 dramatically inhibits it; the inhibitory effect maps to the SDC2 ectodomain (shown by chimera experiments), whereas the SDC1 cytoplasmic tail is required for gene expression but not for clustering or endocytosis. Both form lipid-raft-dependent clusters with PEI polyplexes.","method":"Overexpression of SDC1/SDC2 and cytoplasmic deletion/chimeric constructs in HEK293; GFP reporter gene expression; confocal microscopy; lipid raft disruption","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — domain-swap chimera experiments with defined functional mapping, single lab, multiple construct types","pmids":["18216019"],"is_preprint":false},{"year":2020,"finding":"SDC1 promotes cisplatin resistance in hepatocellular carcinoma cells via activation of the PI3K/AKT pathway; SDC1 knockdown re-sensitizes resistant HepG2 cells to cisplatin, and SDC1 overexpression confers resistance to naïve HepG2 cells. PI3K inhibition overcomes SDC1-mediated resistance.","method":"SDC1 knockdown and overexpression in HepG2; cell viability/proliferation assays; Western blot for p-AKT/AKT; PI3K inhibitor co-treatment","journal":"Human cell","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — gain-and-loss-of-function with signaling pathway placement via PI3K inhibitor, single lab","pmids":["32314115"],"is_preprint":false},{"year":2013,"finding":"Syndecan-1 overexpression in a rat myocardial infarction model reduces post-MI ventricular remodeling and inhibits the p38 MAPK signaling pathway; Sdc1-overexpressing rats show decreased collagen synthesis, reduced apoptosis, and reduced inflammatory cell infiltration.","method":"Intramyocardial injection of adenovirus-carrying Sdc1 cDNA in rat MI model; cardiac function assessment; Western blot for p38 MAPK activation; collagen quantification; histology","journal":"Inflammation","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — in vivo overexpression with signaling pathway assessment (p38 MAPK) and multiple functional readouts, single lab","pmids":["23264165"],"is_preprint":false},{"year":2015,"finding":"Syndecan-1 overexpression in malignant mesothelioma cells downregulates SULF1 (a 6-O-sulfatase), alters heparan sulfate chain composition (increases trisulfated disaccharides 2.5-fold, reduces total HS 2.7-fold), and enhances ERK1/2 activity 6-fold while inhibiting Akt, WNK1, and c-Jun, resulting in G1 cell cycle arrest.","method":"SDC1 overexpression in mesothelioma cells; biochemical HS characterization (disaccharide analysis); Western blot for ERK1/2, Akt, WNK1, c-Jun; cell cycle analysis; correlation with pleural effusion SULF1 levels","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — overexpression with biochemical HS chain characterization and multiple downstream signaling readouts, single lab","pmids":["26210886"],"is_preprint":false},{"year":2018,"finding":"Syndecan-1 controls the miRNA cargo packaged within exosomes exported from lung cancer cells; loss of syndecan-1 shifts exosomal miRNA content toward pro-cancer signaling profiles and augments lung tumorigenesis in cell-based and animal models.","method":"Syndecan-1 loss-of-function in lung cancer cell lines and animal models; exosome isolation; miRNA profiling; tumorigenesis assays","journal":"The American journal of pathology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — KO/KD with exosome miRNA profiling and in vivo tumor model, single lab","pmids":["29355516"],"is_preprint":false}],"current_model":"Syndecan-1 (SDC1/CD138) is a transmembrane heparan sulfate proteoglycan whose conserved cytoplasmic domain mediates internalization of lipoproteins and bacterial pathogens, captures and activates IGF1R to suppress ASK1-dependent apoptosis in myeloma, scaffolds TGM2-FLOT1-BHMT complexes at lysosomes to drive autophagosome–lysosome fusion and radioresistance, modulates RhoA/Rac1 balance and focal adhesion dynamics on collagen matrices, controls macrophage motility through an as-yet undefined cytoskeletal mechanism, regulates exosome biogenesis (in concert with heparanase-mediated HS chain trimming and the syntenin-ALIX pathway), and switches myeloma cells between proliferative (membrane SDC1-high, enhanced IL-6R/IGF1R signaling) and disseminative (SDC1-negative, high motility) states via endocytic recycling of surface SDC1."},"narrative":{"mechanistic_narrative":"Syndecan-1 (SDC1/CD138) is a transmembrane heparan sulfate (and chondroitin sulfate) proteoglycan whose ectodomain glycosaminoglycan chains capture extracellular ligands and whose cytoplasmic domain transduces these binding events into endocytic and cytoskeletal responses [PMID:9294130, PMID:25662098]. Through ligand clustering of its transmembrane/cytoplasmic domain it drives a microfilament- and tyrosine-kinase-dependent internalization route distinct from clathrin-coated pits, mediating uptake of lipoprotein-lipase-enriched lipoproteins and serving as an entry portal for pathogens including Opa-expressing Neisseria gonorrhoeae and HSV-1, with the cytoplasmic tail being required for bacterial uptake [PMID:9294130, PMID:11207564, PMID:21148276]. As a co-adhesion receptor for type I collagen alongside α2β1 integrin, SDC1 governs the RhoA/Rac1 balance, focal adhesion assembly, and cell spreading and motility [PMID:20036233], and its loss in vivo impairs macrophage migration while worsening atherosclerotic burden [PMID:25550207]. In cancer, membrane-retained versus shed SDC1 act as a molecular switch: membrane SDC1 supports proliferation and restrains invasion, whereas the shed ectodomain promotes invasion by downregulating TIMP-1 and E-cadherin [PMID:19126645], and dynamic endocytic recycling of surface CD138 toggles myeloma cells between proliferative IL-6R-high and disseminative motile states [PMID:31439945]. SDC1 captures IGF1R at the myeloma cell surface to sustain IGF1R kinase activity that phosphorylates and inhibits ASK1, suppressing JNK/caspase-3-mediated apoptosis [PMID:27364558]. Following irradiation it scaffolds a TGM2–FLOT1–BHMT complex that traffics from the membrane to lysosomes to coordinate autophagosome–lysosome fusion via the STX17–SNAP29–VAMP8 SNARE machinery, conferring glioblastoma radioresistance [PMID:35913916, PMID:37441590]. SDC1 also regulates exosome biogenesis, supporting heparanase- and syntenin–ALIX-dependent intraluminal budding and controlling exosomal miRNA cargo [PMID:25732677, PMID:29355516].","teleology":[{"year":1997,"claim":"Established that the SDC1 core protein itself mediates ligand internalization through a non-clathrin, microfilament- and tyrosine-kinase-dependent pathway triggered by transmembrane/cytoplasmic clustering, defining SDC1 as an active endocytic receptor rather than a passive co-receptor.","evidence":"CHO cell transfection with chimeric FcR-Syndecan-1 constructs and pharmacological dissection (cytochalasin B, genistein) of lipoprotein internalization kinetics","pmids":["9294130"],"confidence":"High","gaps":["Identity of the cytoplasmic effectors linking clustering to microfilaments not defined","Tyrosine kinase responsible not identified"]},{"year":2000,"claim":"Demonstrated that the SDC1 cytoplasmic tail is functionally required for pathogen entry, generalizing its endocytic role to bacterial invasion and implicating intracellular adaptor motifs.","evidence":"HeLa overexpression of wild-type and cytoplasmic-deletion/point-mutant syndecan-1/-4 constructs with Neisseria gonorrhoeae invasion assays","pmids":["11207564"],"confidence":"High","gaps":["Which SDC1 cytoplasmic adaptor mediates uptake not mapped","Mechanistic link to the lipoprotein internalization route not tested directly"]},{"year":2003,"claim":"Showed SDC1 glycosaminoglycan chains capture the chemokine RANTES/CCL5 and present it to CCR5, positioning SDC1 as a chemokine co-receptor at the macrophage surface.","evidence":"Co-immunoprecipitation and glycosaminidase pre-treatment with binding inhibition assays on monocyte-derived macrophages","pmids":["14637022"],"confidence":"Medium","gaps":["Co-IP from a single lab without reciprocal structural validation","Functional consequence for CCR5 signaling not measured here"]},{"year":2008,"claim":"Defined the membrane-bound versus shed SDC1 dichotomy as a switch between proliferative and invasive phenotypes, linking ectodomain shedding to TIMP-1/E-cadherin downregulation and reduced FGF-2/MAPK signaling.","evidence":"Stable WT, constitutively shed, and uncleavable SDC1 constructs plus siRNA in MCF-7 cells with Matrigel invasion, MAPK Western blot, and microarray","pmids":["19126645"],"confidence":"High","gaps":["Protease driving physiological shedding not identified here","Direct receptor for the shed ectodomain unknown"]},{"year":2009,"claim":"Identified SDC1 as a collagen-I co-adhesion receptor that controls RhoA/Rac1 balance and focal adhesion dynamics, explaining its substrate-specific regulation of motility.","evidence":"siRNA knockdown in squamous carcinoma cells with adhesion, RhoA/Rac1 activation assays, focal adhesion staining, and motility on multiple ECM substrates","pmids":["20036233"],"confidence":"High","gaps":["Cytoplasmic signaling link from SDC1 to RhoA/Rac1 not defined","Role of HS chains versus core protein in collagen co-adhesion not separated"]},{"year":2009,"claim":"Showed SDC1 (with SDC4) is required for chemokine- and apoptosis-related signaling, extending its co-receptor function to RANTES-induced migration and placing it upstream of JunB/FLIP-L-dependent survival.","evidence":"siRNA knockdown with Boyden chamber migration in hepatoma cells, and separate urothelial siRNA with JunB/FLIP-L Western blot plus orthotopic mouse model","pmids":["19632304","19860843"],"confidence":"Medium","gaps":["Mechanistic link from SDC1 to JunB/FLIP-L transcription not established","Direct versus indirect contribution to FAK/PI3K signaling not resolved"]},{"year":2015,"claim":"Established SDC1 as a substrate of heparanase-mediated HS trimming that drives syntenin–ALIX-dependent intraluminal budding and exosome biogenesis, defining a molecular route for SDC1-controlled vesicle secretion.","evidence":"Reciprocal gain/loss of heparanase and syntenin-1/ALIX with exosome fractionation, Western blot, and EM of endosomal membranes","pmids":["25732677"],"confidence":"High","gaps":["How SDC1 cargo selection determines exosome content not defined here","Contribution of the SDC1 cytoplasmic tail to budding not dissected"]},{"year":2015,"claim":"Demonstrated SDC1 chondroitin sulfate chains bind IL-34 and modulate M-CSFR signaling, broadening its ligand repertoire to a CS-dependent cytokine co-receptor function.","evidence":"SPR and radiolabel binding assays, chondroitinase treatment, overexpression/siRNA, and migration assays in myeloid cells","pmids":["25662098"],"confidence":"High","gaps":["Stoichiometry of the SDC1–IL-34–M-CSFR ternary complex unknown","In vivo relevance not established"]},{"year":2016,"claim":"Revealed that SDC1 captures IGF1R to sustain its kinase activity, which phosphorylates and inhibits ASK1 and thereby blocks apoptosis, providing a direct survival mechanism in myeloma and a peptide-based therapeutic strategy.","evidence":"SDC1–IGF1R co-IP, SSTNIGF1R peptide blocking, phospho-specific ASK1 analysis, apoptosis assays, and xenograft validation","pmids":["27364558"],"confidence":"High","gaps":["Structural basis of SDC1–IGF1R capture not resolved","Generality beyond myeloma not tested here"]},{"year":2019,"claim":"Showed that endocytic recycling of surface CD138 dynamically switches myeloma cells between proliferative and disseminative states, connecting SDC1 trafficking to disease behavior.","evidence":"In vivo Vk*MYC myeloma model with flow cytometry, motility imaging, endocytosis assays, and CD138-neutralizing antibody","pmids":["31439945"],"confidence":"High","gaps":["Trafficking machinery controlling recycling not identified","Molecular basis of enhanced IL-6R signaling in CD138-high cells unresolved"]},{"year":2023,"claim":"Defined a post-irradiation SDC1–TGM2–FLOT1–BHMT complex that traffics TGM2 to lysosomes and coordinates autophagosome–lysosome fusion through the STX17–SNAP29–VAMP8 SNARE machinery, establishing SDC1 as a scaffold for autophagic flux and radioresistance.","evidence":"Co-IP defining the multi-protein complex, mRFP-GFP-LC3 flux imaging, EM, knockdowns, and in vivo TGM2-inhibitor GBM models","pmids":["35913916","37441590"],"confidence":"High","gaps":["How irradiation triggers SDC1–TGM2 trafficking not defined","Role of HS/CS chains versus core protein in this scaffold not separated"]},{"year":null,"claim":"How SDC1's distinct cytoplasmic effectors are partitioned across its many roles — endocytosis, collagen-driven Rho/Rac signaling, IGF1R capture, exosome budding, and autophagy scaffolding — remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified map of cytoplasmic-tail adaptor usage across functions","Relative contribution of HS versus CS chains to each ligand interaction not systematized","Structural models of SDC1-containing complexes absent"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0001618","term_label":"virus receptor activity","supporting_discovery_ids":[1,6]},{"term_id":"GO:0038024","term_label":"cargo receptor activity","supporting_discovery_ids":[0]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[2,9,10]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[13,14]},{"term_id":"GO:0098631","term_label":"cell adhesion mediator activity","supporting_discovery_ids":[4]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,4,10,12]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[8,12]},{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[13,14]}],"pathway":[{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[13,14]},{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[8,20]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[10,17]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[10,15]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[2,11]}],"complexes":["SDC1-TGM2-FLOT1-BHMT complex"],"partners":["IGF1R","TGM2","FLOT1","BHMT","SDC4","SDC2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P18827","full_name":"Syndecan-1","aliases":[],"length_aa":310,"mass_kda":32.5,"function":"Cell surface proteoglycan that contains both heparan sulfate and chondroitin sulfate and that links the cytoskeleton to the interstitial matrix (By similarity). Regulates exosome biogenesis in concert with SDCBP and PDCD6IP (PubMed:22660413). Able to induce its own expression in dental mesenchymal cells and also in the neighboring dental epithelial cells via an MSX1-mediated pathway (By similarity)","subcellular_location":"Membrane; Secreted; Secreted, extracellular exosome","url":"https://www.uniprot.org/uniprotkb/P18827/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/SDC1","classification":"Not Classified","n_dependent_lines":106,"n_total_lines":1208,"dependency_fraction":0.08774834437086093},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/SDC1","total_profiled":1310},"omim":[{"mim_id":"607360","title":"LACRITIN; LACRT","url":"https://www.omim.org/entry/607360"},{"mim_id":"606910","title":"BCL2-LIKE 10; BCL2L10","url":"https://www.omim.org/entry/606910"},{"mim_id":"604472","title":"TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY, MEMBER 13; TNFSF13","url":"https://www.omim.org/entry/604472"},{"mim_id":"603423","title":"PR DOMAIN-CONTAINING PROTEIN 1; PRDM1","url":"https://www.omim.org/entry/603423"},{"mim_id":"602217","title":"SYNDECAN-BINDING PROTEIN; SDCBP","url":"https://www.omim.org/entry/602217"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Focal adhesion sites","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"esophagus","ntpm":467.3},{"tissue":"liver","ntpm":471.7},{"tissue":"skin 1","ntpm":422.7}],"url":"https://www.proteinatlas.org/search/SDC1"},"hgnc":{"alias_symbol":["CD138","syndecan","SYND1"],"prev_symbol":["SDC"]},"alphafold":{"accession":"P18827","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P18827","model_url":"https://alphafold.ebi.ac.uk/files/AF-P18827-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P18827-F1-predicted_aligned_error_v6.png","plddt_mean":55.22},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SDC1","jax_strain_url":"https://www.jax.org/strain/search?query=SDC1"},"sequence":{"accession":"P18827","fasta_url":"https://rest.uniprot.org/uniprotkb/P18827.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P18827/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P18827"}},"corpus_meta":[{"pmid":"22033227","id":"PMC_22033227","title":"Molecular functions of syndecan-1 in disease.","date":"2011","source":"Matrix biology : journal of the International Society for Matrix Biology","url":"https://pubmed.ncbi.nlm.nih.gov/22033227","citation_count":289,"is_preprint":false},{"pmid":"25732677","id":"PMC_25732677","title":"Heparanase activates the syndecan-syntenin-ALIX exosome pathway.","date":"2015","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/25732677","citation_count":272,"is_preprint":false},{"pmid":"11580899","id":"PMC_11580899","title":"EphB/syndecan-2 signaling in dendritic spine morphogenesis.","date":"2001","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/11580899","citation_count":262,"is_preprint":false},{"pmid":"14983940","id":"PMC_14983940","title":"CD138 (syndecan-1), a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms.","date":"2004","source":"American journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/14983940","citation_count":209,"is_preprint":false},{"pmid":"9294130","id":"PMC_9294130","title":"The syndecan family of proteoglycans. Novel receptors mediating internalization of atherogenic lipoproteins in vitro.","date":"1997","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/9294130","citation_count":204,"is_preprint":false},{"pmid":"11544026","id":"PMC_11544026","title":"Syndecan-4 and focal adhesion function.","date":"2001","source":"Current opinion in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/11544026","citation_count":183,"is_preprint":false},{"pmid":"23970415","id":"PMC_23970415","title":"Syndecan-4 signaling at a glance.","date":"2013","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/23970415","citation_count":178,"is_preprint":false},{"pmid":"19126645","id":"PMC_19126645","title":"Differential roles for membrane-bound and soluble syndecan-1 (CD138) in breast cancer progression.","date":"2009","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/19126645","citation_count":160,"is_preprint":false},{"pmid":"23374281","id":"PMC_23374281","title":"The heparanase/syndecan-1 axis in cancer: mechanisms and therapies.","date":"2013","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/23374281","citation_count":155,"is_preprint":false},{"pmid":"19535238","id":"PMC_19535238","title":"The signaling mechanisms of syndecan heparan sulfate proteoglycans.","date":"2009","source":"Current opinion in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/19535238","citation_count":153,"is_preprint":false},{"pmid":"26032692","id":"PMC_26032692","title":"Syntenin and syndecan in the biogenesis of exosomes.","date":"2015","source":"Biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/26032692","citation_count":152,"is_preprint":false},{"pmid":"10504290","id":"PMC_10504290","title":"Syndecan-4 and integrins: combinatorial signaling in cell adhesion.","date":"1999","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/10504290","citation_count":144,"is_preprint":false},{"pmid":"12055189","id":"PMC_12055189","title":"Syndecan-2 mediates adhesion and proliferation of colon carcinoma cells.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12055189","citation_count":141,"is_preprint":false},{"pmid":"12087088","id":"PMC_12087088","title":"Syndecan-4 modulates focal adhesion kinase phosphorylation.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12087088","citation_count":119,"is_preprint":false},{"pmid":"11728825","id":"PMC_11728825","title":"Syndecan-4-mediated signalling.","date":"2001","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/11728825","citation_count":113,"is_preprint":false},{"pmid":"21430259","id":"PMC_21430259","title":"Syndecan-1 and syndecan-4 are independent indicators in breast carcinoma.","date":"2011","source":"The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society","url":"https://pubmed.ncbi.nlm.nih.gov/21430259","citation_count":100,"is_preprint":false},{"pmid":"8932508","id":"PMC_8932508","title":"The role of syndecan-1 in malignancies.","date":"1996","source":"Annals of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/8932508","citation_count":100,"is_preprint":false},{"pmid":"16176946","id":"PMC_16176946","title":"Syndecan regulates cell migration and axon guidance in C. elegans.","date":"2005","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/16176946","citation_count":99,"is_preprint":false},{"pmid":"25945286","id":"PMC_25945286","title":"Syndecan-1 and Its Expanding List of Contacts.","date":"2015","source":"Advances in wound care","url":"https://pubmed.ncbi.nlm.nih.gov/25945286","citation_count":98,"is_preprint":false},{"pmid":"16636895","id":"PMC_16636895","title":"Syndecan-1 and syndecan-4 are overexpressed in an estrogen receptor-negative, highly proliferative breast carcinoma subtype.","date":"2006","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/16636895","citation_count":98,"is_preprint":false},{"pmid":"9818173","id":"PMC_9818173","title":"Molecular interactions of the syndecan core proteins.","date":"1998","source":"Current opinion in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/9818173","citation_count":98,"is_preprint":false},{"pmid":"16253987","id":"PMC_16253987","title":"Transmembrane domain-induced oligomerization is crucial for the functions of syndecan-2 and syndecan-4.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16253987","citation_count":92,"is_preprint":false},{"pmid":"31907416","id":"PMC_31907416","title":"Syndecan-4 tunes cell mechanics by activating the kindlin-integrin-RhoA pathway.","date":"2020","source":"Nature materials","url":"https://pubmed.ncbi.nlm.nih.gov/31907416","citation_count":89,"is_preprint":false},{"pmid":"20696709","id":"PMC_20696709","title":"Syndecan-3 and Notch cooperate in regulating adult myogenesis.","date":"2010","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/20696709","citation_count":89,"is_preprint":false},{"pmid":"16198615","id":"PMC_16198615","title":"Syndecan-2.","date":"2005","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/16198615","citation_count":80,"is_preprint":false},{"pmid":"25563413","id":"PMC_25563413","title":"Advances in the molecular functions of syndecan-1 (SDC1/CD138) in the pathogenesis of malignancies.","date":"2014","source":"Critical reviews in oncology/hematology","url":"https://pubmed.ncbi.nlm.nih.gov/25563413","citation_count":80,"is_preprint":false},{"pmid":"11207564","id":"PMC_11207564","title":"Syndecan-1 and syndecan-4 can mediate the invasion of OpaHSPG-expressing Neisseria gonorrhoeae into epithelial cells.","date":"2000","source":"Cellular microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/11207564","citation_count":80,"is_preprint":false},{"pmid":"2759421","id":"PMC_2759421","title":"The Caenorhabditis elegans gene sdc-2 controls sex determination and dosage compensation in XX animals.","date":"1989","source":"Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/2759421","citation_count":78,"is_preprint":false},{"pmid":"3791412","id":"PMC_3791412","title":"sdc-1: a link between sex determination and dosage compensation in C. elegans.","date":"1987","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/3791412","citation_count":78,"is_preprint":false},{"pmid":"25662098","id":"PMC_25662098","title":"Syndecan-1 regulates the biological activities of interleukin-34.","date":"2015","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/25662098","citation_count":78,"is_preprint":false},{"pmid":"24150912","id":"PMC_24150912","title":"CD138 (syndecan-1) expression in health and disease.","date":"2013","source":"Histology and histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/24150912","citation_count":77,"is_preprint":false},{"pmid":"9881599","id":"PMC_9881599","title":"Syndecan proteoglycans and cell adhesion.","date":"1998","source":"Matrix biology : journal of the International Society for Matrix Biology","url":"https://pubmed.ncbi.nlm.nih.gov/9881599","citation_count":74,"is_preprint":false},{"pmid":"21148276","id":"PMC_21148276","title":"Syndecan-1 and syndecan-2 play key roles in herpes simplex virus type-1 infection.","date":"2010","source":"The Journal of general virology","url":"https://pubmed.ncbi.nlm.nih.gov/21148276","citation_count":68,"is_preprint":false},{"pmid":"22841476","id":"PMC_22841476","title":"Syndecan and integrin interactomes: large complexes in small spaces.","date":"2012","source":"Current opinion in structural biology","url":"https://pubmed.ncbi.nlm.nih.gov/22841476","citation_count":64,"is_preprint":false},{"pmid":"9056777","id":"PMC_9056777","title":"SDC-3 coordinates the assembly of a dosage compensation complex on the nematode X chromosome.","date":"1997","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/9056777","citation_count":64,"is_preprint":false},{"pmid":"25179601","id":"PMC_25179601","title":"Shed syndecan-2 inhibits angiogenesis.","date":"2014","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/25179601","citation_count":62,"is_preprint":false},{"pmid":"20083849","id":"PMC_20083849","title":"Syndecan signaling: when, where and why?","date":"2009","source":"Journal of physiology and pharmacology : an official journal of the Polish Physiological Society","url":"https://pubmed.ncbi.nlm.nih.gov/20083849","citation_count":62,"is_preprint":false},{"pmid":"31439945","id":"PMC_31439945","title":"Dynamic CD138 surface expression regulates switch between myeloma growth and dissemination.","date":"2019","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/31439945","citation_count":60,"is_preprint":false},{"pmid":"11904737","id":"PMC_11904737","title":"Syndecan-1 in B lymphoid malignancies.","date":"2002","source":"Annals of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/11904737","citation_count":60,"is_preprint":false},{"pmid":"27364558","id":"PMC_27364558","title":"Syndecan-1 (CD138) Suppresses Apoptosis in Multiple Myeloma by Activating IGF1 Receptor: Prevention by SynstatinIGF1R Inhibits Tumor Growth.","date":"2016","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/27364558","citation_count":60,"is_preprint":false},{"pmid":"8431944","id":"PMC_8431944","title":"Independent domains of the Sdc-3 protein control sex determination and dosage compensation in C. elegans.","date":"1993","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/8431944","citation_count":58,"is_preprint":false},{"pmid":"18207448","id":"PMC_18207448","title":"Syndecan-1 (CD138) and Ki-67 expression in different subtypes of ameloblastomas.","date":"2008","source":"Oral oncology","url":"https://pubmed.ncbi.nlm.nih.gov/18207448","citation_count":57,"is_preprint":false},{"pmid":"35913916","id":"PMC_35913916","title":"SDC1-dependent TGM2 determines radiosensitivity in glioblastoma by coordinating EPG5-mediated fusion of autophagosomes with lysosomes.","date":"2022","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/35913916","citation_count":55,"is_preprint":false},{"pmid":"28940845","id":"PMC_28940845","title":"Emerging roles of syndecan 2 in epithelial and mesenchymal cancer progression.","date":"2017","source":"IUBMB life","url":"https://pubmed.ncbi.nlm.nih.gov/28940845","citation_count":54,"is_preprint":false},{"pmid":"36414669","id":"PMC_36414669","title":"Cholesterol-induced LRP3 downregulation promotes cartilage degeneration in osteoarthritis by targeting Syndecan-4.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/36414669","citation_count":51,"is_preprint":false},{"pmid":"18216019","id":"PMC_18216019","title":"Opposing roles of syndecan-1 and syndecan-2 in polyethyleneimine-mediated gene delivery.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18216019","citation_count":51,"is_preprint":false},{"pmid":"27299886","id":"PMC_27299886","title":"Low Soluble Syndecan-1 Precedes Preeclampsia.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27299886","citation_count":50,"is_preprint":false},{"pmid":"8676253","id":"PMC_8676253","title":"Expression of syndecan-3 and tenascin-C: possible involvement in periosteum development.","date":"1996","source":"Journal of orthopaedic research : official publication of the Orthopaedic Research Society","url":"https://pubmed.ncbi.nlm.nih.gov/8676253","citation_count":50,"is_preprint":false},{"pmid":"20036233","id":"PMC_20036233","title":"Sdc1 negatively modulates carcinoma cell motility and invasion.","date":"2009","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/20036233","citation_count":49,"is_preprint":false},{"pmid":"9548182","id":"PMC_9548182","title":"Expression of syndecan-1 in human placenta and decidua.","date":"1998","source":"Placenta","url":"https://pubmed.ncbi.nlm.nih.gov/9548182","citation_count":49,"is_preprint":false},{"pmid":"23807541","id":"PMC_23807541","title":"Changes of placental syndecan-1 expression in preeclampsia and HELLP syndrome.","date":"2013","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/23807541","citation_count":49,"is_preprint":false},{"pmid":"33921767","id":"PMC_33921767","title":"Syndecan-1 (CD138), Carcinomas and EMT.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33921767","citation_count":48,"is_preprint":false},{"pmid":"33561383","id":"PMC_33561383","title":"Syndecan receptors: pericellular regulators in development and inflammatory disease.","date":"2021","source":"Open biology","url":"https://pubmed.ncbi.nlm.nih.gov/33561383","citation_count":48,"is_preprint":false},{"pmid":"31976021","id":"PMC_31976021","title":"Prevalence of Syndecan-1 (CD138) Expression in Different Kinds of Human Tumors and Normal Tissues.","date":"2019","source":"Disease markers","url":"https://pubmed.ncbi.nlm.nih.gov/31976021","citation_count":48,"is_preprint":false},{"pmid":"25910817","id":"PMC_25910817","title":"Wnt Signaling Cascades and the Roles of Syndecan Proteoglycans.","date":"2015","source":"The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society","url":"https://pubmed.ncbi.nlm.nih.gov/25910817","citation_count":46,"is_preprint":false},{"pmid":"14637022","id":"PMC_14637022","title":"Interaction of RANTES with syndecan-1 and syndecan-4 expressed by human primary macrophages.","date":"2003","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/14637022","citation_count":45,"is_preprint":false},{"pmid":"25550207","id":"PMC_25550207","title":"Syndecan-1 modulates the motility and resolution responses of macrophages.","date":"2014","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/25550207","citation_count":44,"is_preprint":false},{"pmid":"19860843","id":"PMC_19860843","title":"Role of syndecan-1 (CD138) in cell survival of human urothelial carcinoma.","date":"2009","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/19860843","citation_count":44,"is_preprint":false},{"pmid":"19632304","id":"PMC_19632304","title":"Syndecan-1 and syndecan-4 are involved in RANTES/CCL5-induced migration and invasion of human hepatoma cells.","date":"2009","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/19632304","citation_count":44,"is_preprint":false},{"pmid":"20201998","id":"PMC_20201998","title":"Characterisation and relevance of CD138-negative plasma cells in plasma cell myeloma.","date":"2010","source":"International journal of laboratory hematology","url":"https://pubmed.ncbi.nlm.nih.gov/20201998","citation_count":41,"is_preprint":false},{"pmid":"10050727","id":"PMC_10050727","title":"Syndecan-1 (CD138) expression in human non-Hodgkin lymphomas.","date":"1999","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/10050727","citation_count":41,"is_preprint":false},{"pmid":"35584326","id":"PMC_35584326","title":"Targeting syndecan-1: new opportunities in cancer therapy.","date":"2022","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/35584326","citation_count":40,"is_preprint":false},{"pmid":"27062540","id":"PMC_27062540","title":"Soluble syndecan-1 (SDC1) serum level as an independent pre-operative predictor of cancer-specific survival in prostate cancer.","date":"2016","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/27062540","citation_count":39,"is_preprint":false},{"pmid":"38677244","id":"PMC_38677244","title":"NETs induce ferroptosis of endothelial cells in LPS-ALI through SDC-1/HS and downstream pathways.","date":"2024","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/38677244","citation_count":37,"is_preprint":false},{"pmid":"26796346","id":"PMC_26796346","title":"Syndecan-4 in intervertebral disc and cartilage: Saint or synner?","date":"2016","source":"Matrix biology : journal of the International Society for Matrix Biology","url":"https://pubmed.ncbi.nlm.nih.gov/26796346","citation_count":37,"is_preprint":false},{"pmid":"29355516","id":"PMC_29355516","title":"Syndecan-1 Controls Lung Tumorigenesis by Regulating miRNAs Packaged in Exosomes.","date":"2018","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/29355516","citation_count":37,"is_preprint":false},{"pmid":"34282767","id":"PMC_34282767","title":"Syndecan-4 in Tumor Cell Motility.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34282767","citation_count":36,"is_preprint":false},{"pmid":"31998313","id":"PMC_31998313","title":"Syndecan-3 in Inflammation and Angiogenesis.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31998313","citation_count":36,"is_preprint":false},{"pmid":"9822999","id":"PMC_9822999","title":"Syndecan-3 in limb skeletal development.","date":"1998","source":"Microscopy research and technique","url":"https://pubmed.ncbi.nlm.nih.gov/9822999","citation_count":33,"is_preprint":false},{"pmid":"22745764","id":"PMC_22745764","title":"Syndecan-1 enhances proliferation, migration and metastasis of HT-1080 cells in cooperation with syndecan-2.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22745764","citation_count":33,"is_preprint":false},{"pmid":"37441590","id":"PMC_37441590","title":"SDC1-TGM2-FLOT1-BHMT complex determines radiosensitivity of glioblastoma by influencing the fusion of autophagosomes with lysosomes.","date":"2023","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/37441590","citation_count":32,"is_preprint":false},{"pmid":"32274708","id":"PMC_32274708","title":"Involvement of Syndecan-1 and Heparanase in Cancer and Inflammation.","date":"2020","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/32274708","citation_count":32,"is_preprint":false},{"pmid":"20510012","id":"PMC_20510012","title":"Shedding; towards a new paradigm of syndecan function in cancer.","date":"2010","source":"BMB reports","url":"https://pubmed.ncbi.nlm.nih.gov/20510012","citation_count":31,"is_preprint":false},{"pmid":"31810587","id":"PMC_31810587","title":"Relationship between SDC1 and cadherin signalling activation in cancer.","date":"2019","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/31810587","citation_count":29,"is_preprint":false},{"pmid":"32329146","id":"PMC_32329146","title":"Chronic endometritis and reproductive failure: Role of syndecan-1.","date":"2020","source":"American journal of reproductive immunology (New York, N.Y. : 1989)","url":"https://pubmed.ncbi.nlm.nih.gov/32329146","citation_count":29,"is_preprint":false},{"pmid":"32314115","id":"PMC_32314115","title":"SDC1 promotes cisplatin resistance in hepatic carcinoma cells via PI3K-AKT pathway.","date":"2020","source":"Human cell","url":"https://pubmed.ncbi.nlm.nih.gov/32314115","citation_count":28,"is_preprint":false},{"pmid":"30826971","id":"PMC_30826971","title":"Syndecan-1 in Liver Diseases.","date":"2019","source":"Pathology oncology research : POR","url":"https://pubmed.ncbi.nlm.nih.gov/30826971","citation_count":26,"is_preprint":false},{"pmid":"34386495","id":"PMC_34386495","title":"MiR-665 Regulates Vascular Smooth Muscle Cell Senescence by Interacting With LncRNA GAS5/SDC1.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/34386495","citation_count":26,"is_preprint":false},{"pmid":"25805752","id":"PMC_25805752","title":"USP38, FREM3, SDC1, DDC, and LOC727982 Gene Polymorphisms and Differential Susceptibility to Severe Malaria in Tanzania.","date":"2015","source":"The Journal of infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/25805752","citation_count":24,"is_preprint":false},{"pmid":"23988031","id":"PMC_23988031","title":"Fibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) are potential biomarkers for putative circulating CD15+/CD30+ cells in poor outcome Hodgkin lymphoma patients.","date":"2013","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/23988031","citation_count":24,"is_preprint":false},{"pmid":"12975609","id":"PMC_12975609","title":"Syndecan-4: dispensable or indispensable?","date":"2002","source":"Glycoconjugate journal","url":"https://pubmed.ncbi.nlm.nih.gov/12975609","citation_count":23,"is_preprint":false},{"pmid":"33117401","id":"PMC_33117401","title":"Hypoxia Promotes Syndecan-3 Expression in the Tumor Microenvironment.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33117401","citation_count":23,"is_preprint":false},{"pmid":"21915520","id":"PMC_21915520","title":"Syndecan-1 (CD138) and Ki-67 expression in odontogenic cystic lesions.","date":"2011","source":"Brazilian dental journal","url":"https://pubmed.ncbi.nlm.nih.gov/21915520","citation_count":23,"is_preprint":false},{"pmid":"29033837","id":"PMC_29033837","title":"Dioscin Inhibits HSC-T6 Cell Migration via Adjusting SDC-4 Expression: Insights from iTRAQ-Based Quantitative Proteomics.","date":"2017","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29033837","citation_count":23,"is_preprint":false},{"pmid":"30308478","id":"PMC_30308478","title":"Beyond RGD; nanoclusters of syndecan- and integrin-binding ligands synergistically enhance cell/material interactions.","date":"2018","source":"Biomaterials","url":"https://pubmed.ncbi.nlm.nih.gov/30308478","citation_count":23,"is_preprint":false},{"pmid":"20598296","id":"PMC_20598296","title":"Syndecan- and integrin-binding peptides synergistically accelerate cell adhesion.","date":"2010","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/20598296","citation_count":23,"is_preprint":false},{"pmid":"26954291","id":"PMC_26954291","title":"Anti-human CD138 monoclonal antibodies and their bispecific formats: generation and characterization.","date":"2016","source":"Immunopharmacology and immunotoxicology","url":"https://pubmed.ncbi.nlm.nih.gov/26954291","citation_count":22,"is_preprint":false},{"pmid":"35704700","id":"PMC_35704700","title":"Syndecan-1 in liver pathophysiology.","date":"2022","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/35704700","citation_count":21,"is_preprint":false},{"pmid":"37121557","id":"PMC_37121557","title":"CircKIF4A combines EIF4A3 to stabilize SDC1 expression to activate c-src/FAK and promotes TNBC progression.","date":"2023","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/37121557","citation_count":21,"is_preprint":false},{"pmid":"30562054","id":"PMC_30562054","title":"Lung Adenocarcinoma Syndecan-2 Potentiates Cell Invasiveness.","date":"2019","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/30562054","citation_count":21,"is_preprint":false},{"pmid":"25979339","id":"PMC_25979339","title":"Trans-regulation of Syndecan Functions by Hetero-oligomerization.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25979339","citation_count":21,"is_preprint":false},{"pmid":"23264165","id":"PMC_23264165","title":"Sdc1 overexpression inhibits the p38 MAPK pathway and lessens fibrotic ventricular remodeling in MI rats.","date":"2013","source":"Inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/23264165","citation_count":20,"is_preprint":false},{"pmid":"15968398","id":"PMC_15968398","title":"Expression and function of syndecan-4 in human platelets.","date":"2005","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/15968398","citation_count":20,"is_preprint":false},{"pmid":"17576238","id":"PMC_17576238","title":"Switch in syndecan-1 and syndecan-4 expression controls maturation associated dendritic cell motility.","date":"2007","source":"Experimental dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/17576238","citation_count":20,"is_preprint":false},{"pmid":"26210886","id":"PMC_26210886","title":"Syndecan-1 alters heparan sulfate composition and signaling pathways in malignant mesothelioma.","date":"2015","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/26210886","citation_count":20,"is_preprint":false},{"pmid":"29523771","id":"PMC_29523771","title":"Glycobiology of syndecan-1 in bacterial infections.","date":"2018","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/29523771","citation_count":19,"is_preprint":false},{"pmid":"27041028","id":"PMC_27041028","title":"Syndecan-4 expression is upregulated in endometriosis and contributes to an invasive phenotype.","date":"2016","source":"Fertility and sterility","url":"https://pubmed.ncbi.nlm.nih.gov/27041028","citation_count":19,"is_preprint":false},{"pmid":"25344834","id":"PMC_25344834","title":"Syndecan-1 regulates adipogenesis: new insights in dedifferentiated liposarcoma tumorigenesis.","date":"2014","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/25344834","citation_count":19,"is_preprint":false},{"pmid":"23137022","id":"PMC_23137022","title":"Hepatic expression and serum levels of syndecan 1 (CD138) in patients with nonalcoholic fatty liver disease.","date":"2012","source":"Scandinavian journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/23137022","citation_count":19,"is_preprint":false},{"pmid":"25848534","id":"PMC_25848534","title":"Role of syndecan-2 in osteoblast biology and pathology.","date":"2015","source":"BoneKEy reports","url":"https://pubmed.ncbi.nlm.nih.gov/25848534","citation_count":16,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":45373,"output_tokens":5886,"usd":0.112204,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14420,"output_tokens":4485,"usd":0.092112,"stage2_stop_reason":"end_turn"},"total_usd":0.204316,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"Syndecan-1 core protein directly mediates internalization of lipoprotein lipase-enriched lipoproteins via a pathway distinct from clathrin-coated pits; the internalization requires microfilaments (cytochalasin B-sensitive) and tyrosine kinase activity (genistein-sensitive), and is triggered by ligand clustering of the transmembrane/cytoplasmic domain.\",\n      \"method\": \"CHO cell transfection with syndecan-1 expression vector; chimeric FcR-Synd1 construct; internalization kinetics and pharmacological inhibitors (cytochalasin B, genistein)\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 / Strong — chimeric construct reconstitution, multiple pharmacological dissections, kinetic comparisons with coated-pit pathway in a single rigorous study\",\n      \"pmids\": [\"9294130\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Syndecan-1 (and syndecan-4) mediate invasion of OpaHSPG-expressing Neisseria gonorrhoeae into epithelial cells; the intracellular domains of both syndecans are required for bacterial uptake, as dominant-negative truncation mutants lacking the cytoplasmic tail abolish invasion. Syndecan-4 mutants lacking the PKC/PIP2-binding dimerization motif or the C-terminal EFYA motif (which binds syntenin/CASK) also lose invasion capacity.\",\n      \"method\": \"HeLa cell overexpression of wild-type and cytoplasmic-deletion/point-mutant syndecan-1 and -4 constructs; bacterial invasion assay; co-localization by microscopy\",\n      \"journal\": \"Cellular microbiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — structure-function mutagenesis with multiple mutant constructs and functional invasion readout in a single focused study\",\n      \"pmids\": [\"11207564\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"RANTES/CCL5 specifically binds to syndecan-1 and syndecan-4 (but not syndecan-2) on human monocyte-derived macrophages; this binding is dependent on the glycosaminoglycan chains and facilitates subsequent interaction of RANTES with the GPCR CCR5.\",\n      \"method\": \"Co-immunoprecipitation; glycosaminidase pre-treatment of cells; binding inhibition assays\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — co-IP with enzymatic chain-removal confirmation, single lab, two orthogonal methods\",\n      \"pmids\": [\"14637022\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Membrane-bound syndecan-1 promotes MCF-7 cell proliferation and inhibits invasiveness, whereas constitutively shed (soluble) syndecan-1 decreases proliferation and promotes invasion into Matrigel; FGF-2-mediated MAPK signaling is reduced by siRNA knockdown of syndecan-1. Soluble SDC1 downregulates TIMP-1 and E-cadherin, accounting for the pro-invasive switch.\",\n      \"method\": \"Stable transfection of wild-type, constitutively shed, and uncleavable SDC1 constructs in MCF-7; siRNA knockdown; Matrigel invasion; Western blot for MAPK signaling; Affymetrix microarray\",\n      \"journal\": \"Carcinogenesis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple construct types (WT/shed/uncleavable), siRNA, functional invasion and signaling readouts, single lab with orthogonal methods\",\n      \"pmids\": [\"19126645\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Syndecan-1 acts as a co-adhesion receptor for Type I collagen (alongside α2β1 integrin) in squamous cell carcinoma cells; siRNA-mediated depletion of Sdc1 reduces adhesion to collagen I, abolishes adhesion-induced RhoA activation, strongly activates Rac1, reduces focal adhesion plaque formation, and enhances cell spreading and motility specifically on collagen I substrates.\",\n      \"method\": \"siRNA knockdown; adhesion assays; RhoA/Rac1 activation assays; focal adhesion staining; cell motility on various ECM substrates\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — specific siRNA KD with multiple orthogonal functional and signaling readouts, single lab\",\n      \"pmids\": [\"20036233\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Syndecan-1 and syndecan-4 are required for RANTES/CCL5-induced migration and invasion of human hepatoma cells; siRNA knockdown of SDC1 or SDC4 reduces cell chemotaxis and spreading induced by RANTES/CCL5; the chemokine effect depends on FAK phosphorylation, PI3K, MAPK, and Rho kinase activation.\",\n      \"method\": \"siRNA knockdown of SDC1 and SDC4; pharmacological inhibitors; Boyden chamber migration/invasion assay; Western blot for FAK phosphorylation\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA KD of two specific syndecans with functional migration readout and signaling pathway dissection, single lab\",\n      \"pmids\": [\"19632304\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Syndecan-1 and syndecan-2 gene silencing by RNA interference reduces HSV-1 entry and plaque formation in host cells; conversely, HSV-1 infection increases syndecan-1 and syndecan-2 protein synthesis and surface heparan sulfate expression.\",\n      \"method\": \"siRNA knockdown of syndecan-1 and syndecan-2; viral entry and plaque formation assays; flow cytometry\",\n      \"journal\": \"The Journal of general virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — specific siRNA KD with viral entry and plaque readouts, single lab, single method type\",\n      \"pmids\": [\"21148276\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Syndecan-1 overexpression in HT-1080 fibrosarcoma cells promotes proliferation and chemotaxis via upregulation of syndecan-2; the pro-migratory effect of syndecan-1 is abolished when syndecan-2 is silenced. The ectodomain of syndecan-1 is dispensable for cytoplasmic-domain-mediated proliferative effects in vitro. Syndecan-1 overexpression activates IGF1R and increases Ets-1 expression.\",\n      \"method\": \"Transfection of full-length and truncated syndecan-1 constructs; syndecan-2 antisense silencing; in vitro proliferation, migration, invasion assays; Western blot for IGF1R and Ets-1; in vivo xenograft\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple construct types plus silencing rescue experiments with orthogonal readouts, single lab\",\n      \"pmids\": [\"22745764\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Heparanase stimulates the exosomal secretion of syntenin-1, syndecan and CD63 in a concentration-dependent and syntenin-1/ALIX-dependent manner by trimming the heparan sulfate chains on syndecans; syndecans (but not glypicans) support exosome biogenesis in heparanase-exposed cells. Heparanase stimulates intraluminal budding of syndecan and syntenin-1 in endosomes, dependent on the syntenin-ALIX interaction.\",\n      \"method\": \"Overexpression/knockdown of heparanase and syntenin-1/ALIX in cell lines; exosome fractionation and Western blot; electron microscopy of endosomal membranes; glypican vs syndecan comparison\",\n      \"journal\": \"Cell research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal gain-and-loss-of-function, multiple orthogonal methods (biochemical fractionation, EM), replicated across multiple cargo and receptor types in one rigorous study\",\n      \"pmids\": [\"25732677\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Syndecan-1 binds IL-34 via its chondroitin sulfate chains and modulates IL-34-induced M-CSFR signaling; syndecan-1 overexpression or a blocking anti-syndecan antibody alters M-CSFR phosphorylation patterns. IL-34-induced migration of myeloid cells (THP-1, M2a macrophages) is syndecan-1 dependent.\",\n      \"method\": \"Scatchard and binding inhibition assays with 125I-radiolabelled cytokines; surface plasmon resonance; chondroitinase treatment; syndecan-1 overexpression and siRNA; Western blot for M-CSFR phosphorylation; migration assays with blocking antibody\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — direct binding assays (SPR, radiolabel), enzymatic chain removal, overexpression/silencing, and functional migration readout in one study\",\n      \"pmids\": [\"25662098\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Syndecan-1 (CD138) captures IGF1 receptor (IGF1R) on multiple myeloma cell surfaces, maintaining constitutive and ligand-induced IGF1R kinase activity that phosphorylates and inhibits ASK1 (at Tyr and Ser83/Ser966), thereby suppressing ASK1-dependent, JNK/caspase-3-mediated apoptosis. A peptide inhibitor (SSTNIGF1R) that blocks IGF1R capture by SDC1 restores ASK1 activity and triggers apoptosis.\",\n      \"method\": \"Co-immunoprecipitation of SDC1 and IGF1R; peptide inhibitor (SSTNIGF1R) blocking assay; Western blot for IGF1R kinase activity, ASK1 phosphorylation; apoptosis assays; in vivo xenograft tumor model\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — co-IP, peptide-based mechanistic rescue, phospho-specific signaling analysis, and in vivo validation in one study\",\n      \"pmids\": [\"27364558\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Syndecan-1 deficiency (Sdc-1−/− mice) causes impaired macrophage migration and enhanced adhesion in M2 macrophages; Sdc-1−/− macrophages show delayed lymphatic clearance in thioglycollate-induced peritonitis and greater atherosclerotic plaque burden in ApoE−/−Sdc-1−/− mice on Western diet.\",\n      \"method\": \"Sdc-1 null mouse model; in vitro migration and adhesion assays; in vivo thioglycollate peritonitis model; ApoE/Sdc-1 double knockout atherosclerosis model\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with defined cellular phenotype (migration/adhesion), in vivo disease model confirmation, single lab with multiple orthogonal readouts\",\n      \"pmids\": [\"25550207\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Dynamic endocytic recycling of CD138/syndecan-1 surface expression in myeloma cells regulates a switch between high-proliferation/low-motility (CD138-high) and low-proliferation/high-motility (CD138-negative) states; neutralizing CD138 rapidly triggers migration and intravasation in vivo, leading to increased bone dissemination. CD138-high myeloma cells show enhanced IL-6R signaling and superior engraftment.\",\n      \"method\": \"In vivo Vk*MYC murine myeloma model; flow cytometry; in vivo motility imaging; endocytosis trafficking assays; CD138-neutralizing antibody; bortezomib combination treatment\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo genetic/antibody model with defined cellular phenotypes and mechanistic endocytic trafficking experiments, multiple orthogonal readouts\",\n      \"pmids\": [\"31439945\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"After irradiation, SDC1 binds TGM2 and transports it from the cell membrane to lysosomes; TGM2 then binds LC3 on autophagosomes via LC3-interacting regions (LIRs) to coordinate autophagosome-lysosome fusion, enabling EPG5 to stabilize the STX17-SNAP29-VAMP8 SNARE complex. SDC1-TGM2 interaction is required for autophagic flux and radioresistance in glioblastoma.\",\n      \"method\": \"Co-immunoprecipitation; confocal microscopy (mRFP-GFP-LC3 flux reporter); transmission electron microscopy; Western blot; SDC1/TGM2 knockdown; TGM2 inhibitor (cystamine) in vivo mouse GBM model\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP protein complex, live-cell autophagic flux imaging, EM, and in vivo pharmacological validation in one study\",\n      \"pmids\": [\"35913916\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SDC1 forms a complex with TGM2, FLOT1, and BHMT to maintain autophagic flux: after irradiation SDC1 carries TGM2 from the cell membrane into cytoplasm and to lysosomes via FLOT1; TGM2 then recognizes BHMT on autophagosomes to coordinate autophagosome-lysosome encounter. This SDC1-TGM2-FLOT1-BHMT complex promotes GBM radioresistance.\",\n      \"method\": \"Co-IP assays; colony formation; flow cytometry; qPCR; Western blot; mRFP-GFP-LC3; transmission electron microscopy; immunofluorescence\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP defining a four-protein complex, multiple orthogonal cellular and structural methods, functionally linked to radioresistance phenotype\",\n      \"pmids\": [\"37441590\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Syndecan-1 knockdown in urothelial carcinoma cells (siRNA) downregulates transcription factor JunB and the long isoform of FLIP (FLIP-L), leading to pan-caspase-inhibitor-sensitive apoptosis. In vivo transurethral siRNA injection reduces SDC1 expression and tumor growth in an orthotopic mouse bladder cancer model.\",\n      \"method\": \"siRNA transfection; Western blot for JunB and FLIP-L; apoptosis assays with pan-caspase inhibitor; orthotopic mouse bladder cancer model\",\n      \"journal\": \"Cancer science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA KD with defined apoptotic pathway placement (JunB/FLIP-L) and in vivo confirmation, single lab\",\n      \"pmids\": [\"19860843\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Syndecan-1 and syndecan-2 have opposing roles in PEI-mediated gene delivery: SDC1 overexpression enhances transfection efficiency, while SDC2 dramatically inhibits it; the inhibitory effect maps to the SDC2 ectodomain (shown by chimera experiments), whereas the SDC1 cytoplasmic tail is required for gene expression but not for clustering or endocytosis. Both form lipid-raft-dependent clusters with PEI polyplexes.\",\n      \"method\": \"Overexpression of SDC1/SDC2 and cytoplasmic deletion/chimeric constructs in HEK293; GFP reporter gene expression; confocal microscopy; lipid raft disruption\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — domain-swap chimera experiments with defined functional mapping, single lab, multiple construct types\",\n      \"pmids\": [\"18216019\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"SDC1 promotes cisplatin resistance in hepatocellular carcinoma cells via activation of the PI3K/AKT pathway; SDC1 knockdown re-sensitizes resistant HepG2 cells to cisplatin, and SDC1 overexpression confers resistance to naïve HepG2 cells. PI3K inhibition overcomes SDC1-mediated resistance.\",\n      \"method\": \"SDC1 knockdown and overexpression in HepG2; cell viability/proliferation assays; Western blot for p-AKT/AKT; PI3K inhibitor co-treatment\",\n      \"journal\": \"Human cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — gain-and-loss-of-function with signaling pathway placement via PI3K inhibitor, single lab\",\n      \"pmids\": [\"32314115\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Syndecan-1 overexpression in a rat myocardial infarction model reduces post-MI ventricular remodeling and inhibits the p38 MAPK signaling pathway; Sdc1-overexpressing rats show decreased collagen synthesis, reduced apoptosis, and reduced inflammatory cell infiltration.\",\n      \"method\": \"Intramyocardial injection of adenovirus-carrying Sdc1 cDNA in rat MI model; cardiac function assessment; Western blot for p38 MAPK activation; collagen quantification; histology\",\n      \"journal\": \"Inflammation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — in vivo overexpression with signaling pathway assessment (p38 MAPK) and multiple functional readouts, single lab\",\n      \"pmids\": [\"23264165\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Syndecan-1 overexpression in malignant mesothelioma cells downregulates SULF1 (a 6-O-sulfatase), alters heparan sulfate chain composition (increases trisulfated disaccharides 2.5-fold, reduces total HS 2.7-fold), and enhances ERK1/2 activity 6-fold while inhibiting Akt, WNK1, and c-Jun, resulting in G1 cell cycle arrest.\",\n      \"method\": \"SDC1 overexpression in mesothelioma cells; biochemical HS characterization (disaccharide analysis); Western blot for ERK1/2, Akt, WNK1, c-Jun; cell cycle analysis; correlation with pleural effusion SULF1 levels\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — overexpression with biochemical HS chain characterization and multiple downstream signaling readouts, single lab\",\n      \"pmids\": [\"26210886\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Syndecan-1 controls the miRNA cargo packaged within exosomes exported from lung cancer cells; loss of syndecan-1 shifts exosomal miRNA content toward pro-cancer signaling profiles and augments lung tumorigenesis in cell-based and animal models.\",\n      \"method\": \"Syndecan-1 loss-of-function in lung cancer cell lines and animal models; exosome isolation; miRNA profiling; tumorigenesis assays\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — KO/KD with exosome miRNA profiling and in vivo tumor model, single lab\",\n      \"pmids\": [\"29355516\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"Syndecan-1 (SDC1/CD138) is a transmembrane heparan sulfate proteoglycan whose conserved cytoplasmic domain mediates internalization of lipoproteins and bacterial pathogens, captures and activates IGF1R to suppress ASK1-dependent apoptosis in myeloma, scaffolds TGM2-FLOT1-BHMT complexes at lysosomes to drive autophagosome–lysosome fusion and radioresistance, modulates RhoA/Rac1 balance and focal adhesion dynamics on collagen matrices, controls macrophage motility through an as-yet undefined cytoskeletal mechanism, regulates exosome biogenesis (in concert with heparanase-mediated HS chain trimming and the syntenin-ALIX pathway), and switches myeloma cells between proliferative (membrane SDC1-high, enhanced IL-6R/IGF1R signaling) and disseminative (SDC1-negative, high motility) states via endocytic recycling of surface SDC1.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"Syndecan-1 (SDC1/CD138) is a transmembrane heparan sulfate (and chondroitin sulfate) proteoglycan whose ectodomain glycosaminoglycan chains capture extracellular ligands and whose cytoplasmic domain transduces these binding events into endocytic and cytoskeletal responses [#0, #9]. Through ligand clustering of its transmembrane/cytoplasmic domain it drives a microfilament- and tyrosine-kinase-dependent internalization route distinct from clathrin-coated pits, mediating uptake of lipoprotein-lipase-enriched lipoproteins and serving as an entry portal for pathogens including Opa-expressing Neisseria gonorrhoeae and HSV-1, with the cytoplasmic tail being required for bacterial uptake [#0, #1, #6]. As a co-adhesion receptor for type I collagen alongside α2β1 integrin, SDC1 governs the RhoA/Rac1 balance, focal adhesion assembly, and cell spreading and motility [#4], and its loss in vivo impairs macrophage migration while worsening atherosclerotic burden [#11]. In cancer, membrane-retained versus shed SDC1 act as a molecular switch: membrane SDC1 supports proliferation and restrains invasion, whereas the shed ectodomain promotes invasion by downregulating TIMP-1 and E-cadherin [#3], and dynamic endocytic recycling of surface CD138 toggles myeloma cells between proliferative IL-6R-high and disseminative motile states [#12]. SDC1 captures IGF1R at the myeloma cell surface to sustain IGF1R kinase activity that phosphorylates and inhibits ASK1, suppressing JNK/caspase-3-mediated apoptosis [#10]. Following irradiation it scaffolds a TGM2–FLOT1–BHMT complex that traffics from the membrane to lysosomes to coordinate autophagosome–lysosome fusion via the STX17–SNAP29–VAMP8 SNARE machinery, conferring glioblastoma radioresistance [#13, #14]. SDC1 also regulates exosome biogenesis, supporting heparanase- and syntenin–ALIX-dependent intraluminal budding and controlling exosomal miRNA cargo [#8, #20].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Established that the SDC1 core protein itself mediates ligand internalization through a non-clathrin, microfilament- and tyrosine-kinase-dependent pathway triggered by transmembrane/cytoplasmic clustering, defining SDC1 as an active endocytic receptor rather than a passive co-receptor.\",\n      \"evidence\": \"CHO cell transfection with chimeric FcR-Syndecan-1 constructs and pharmacological dissection (cytochalasin B, genistein) of lipoprotein internalization kinetics\",\n      \"pmids\": [\"9294130\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the cytoplasmic effectors linking clustering to microfilaments not defined\", \"Tyrosine kinase responsible not identified\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Demonstrated that the SDC1 cytoplasmic tail is functionally required for pathogen entry, generalizing its endocytic role to bacterial invasion and implicating intracellular adaptor motifs.\",\n      \"evidence\": \"HeLa overexpression of wild-type and cytoplasmic-deletion/point-mutant syndecan-1/-4 constructs with Neisseria gonorrhoeae invasion assays\",\n      \"pmids\": [\"11207564\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which SDC1 cytoplasmic adaptor mediates uptake not mapped\", \"Mechanistic link to the lipoprotein internalization route not tested directly\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Showed SDC1 glycosaminoglycan chains capture the chemokine RANTES/CCL5 and present it to CCR5, positioning SDC1 as a chemokine co-receptor at the macrophage surface.\",\n      \"evidence\": \"Co-immunoprecipitation and glycosaminidase pre-treatment with binding inhibition assays on monocyte-derived macrophages\",\n      \"pmids\": [\"14637022\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Co-IP from a single lab without reciprocal structural validation\", \"Functional consequence for CCR5 signaling not measured here\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Defined the membrane-bound versus shed SDC1 dichotomy as a switch between proliferative and invasive phenotypes, linking ectodomain shedding to TIMP-1/E-cadherin downregulation and reduced FGF-2/MAPK signaling.\",\n      \"evidence\": \"Stable WT, constitutively shed, and uncleavable SDC1 constructs plus siRNA in MCF-7 cells with Matrigel invasion, MAPK Western blot, and microarray\",\n      \"pmids\": [\"19126645\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Protease driving physiological shedding not identified here\", \"Direct receptor for the shed ectodomain unknown\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Identified SDC1 as a collagen-I co-adhesion receptor that controls RhoA/Rac1 balance and focal adhesion dynamics, explaining its substrate-specific regulation of motility.\",\n      \"evidence\": \"siRNA knockdown in squamous carcinoma cells with adhesion, RhoA/Rac1 activation assays, focal adhesion staining, and motility on multiple ECM substrates\",\n      \"pmids\": [\"20036233\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cytoplasmic signaling link from SDC1 to RhoA/Rac1 not defined\", \"Role of HS chains versus core protein in collagen co-adhesion not separated\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Showed SDC1 (with SDC4) is required for chemokine- and apoptosis-related signaling, extending its co-receptor function to RANTES-induced migration and placing it upstream of JunB/FLIP-L-dependent survival.\",\n      \"evidence\": \"siRNA knockdown with Boyden chamber migration in hepatoma cells, and separate urothelial siRNA with JunB/FLIP-L Western blot plus orthotopic mouse model\",\n      \"pmids\": [\"19632304\", \"19860843\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanistic link from SDC1 to JunB/FLIP-L transcription not established\", \"Direct versus indirect contribution to FAK/PI3K signaling not resolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Established SDC1 as a substrate of heparanase-mediated HS trimming that drives syntenin–ALIX-dependent intraluminal budding and exosome biogenesis, defining a molecular route for SDC1-controlled vesicle secretion.\",\n      \"evidence\": \"Reciprocal gain/loss of heparanase and syntenin-1/ALIX with exosome fractionation, Western blot, and EM of endosomal membranes\",\n      \"pmids\": [\"25732677\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How SDC1 cargo selection determines exosome content not defined here\", \"Contribution of the SDC1 cytoplasmic tail to budding not dissected\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Demonstrated SDC1 chondroitin sulfate chains bind IL-34 and modulate M-CSFR signaling, broadening its ligand repertoire to a CS-dependent cytokine co-receptor function.\",\n      \"evidence\": \"SPR and radiolabel binding assays, chondroitinase treatment, overexpression/siRNA, and migration assays in myeloid cells\",\n      \"pmids\": [\"25662098\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry of the SDC1–IL-34–M-CSFR ternary complex unknown\", \"In vivo relevance not established\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Revealed that SDC1 captures IGF1R to sustain its kinase activity, which phosphorylates and inhibits ASK1 and thereby blocks apoptosis, providing a direct survival mechanism in myeloma and a peptide-based therapeutic strategy.\",\n      \"evidence\": \"SDC1–IGF1R co-IP, SSTNIGF1R peptide blocking, phospho-specific ASK1 analysis, apoptosis assays, and xenograft validation\",\n      \"pmids\": [\"27364558\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of SDC1–IGF1R capture not resolved\", \"Generality beyond myeloma not tested here\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showed that endocytic recycling of surface CD138 dynamically switches myeloma cells between proliferative and disseminative states, connecting SDC1 trafficking to disease behavior.\",\n      \"evidence\": \"In vivo Vk*MYC myeloma model with flow cytometry, motility imaging, endocytosis assays, and CD138-neutralizing antibody\",\n      \"pmids\": [\"31439945\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Trafficking machinery controlling recycling not identified\", \"Molecular basis of enhanced IL-6R signaling in CD138-high cells unresolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defined a post-irradiation SDC1–TGM2–FLOT1–BHMT complex that traffics TGM2 to lysosomes and coordinates autophagosome–lysosome fusion through the STX17–SNAP29–VAMP8 SNARE machinery, establishing SDC1 as a scaffold for autophagic flux and radioresistance.\",\n      \"evidence\": \"Co-IP defining the multi-protein complex, mRFP-GFP-LC3 flux imaging, EM, knockdowns, and in vivo TGM2-inhibitor GBM models\",\n      \"pmids\": [\"35913916\", \"37441590\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How irradiation triggers SDC1–TGM2 trafficking not defined\", \"Role of HS/CS chains versus core protein in this scaffold not separated\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How SDC1's distinct cytoplasmic effectors are partitioned across its many roles — endocytosis, collagen-driven Rho/Rac signaling, IGF1R capture, exosome budding, and autophagy scaffolding — remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified map of cytoplasmic-tail adaptor usage across functions\", \"Relative contribution of HS versus CS chains to each ligand interaction not systematized\", \"Structural models of SDC1-containing complexes absent\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0001618\", \"supporting_discovery_ids\": [1, 6]},\n      {\"term_id\": \"GO:0038024\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [2, 9, 10]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [13, 14]},\n      {\"term_id\": \"GO:0098631\", \"supporting_discovery_ids\": [4]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 4, 10, 12]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [8, 12]},\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [13, 14]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [13, 14]},\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [8, 20]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [10, 17]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [10, 15]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [2, 11]}\n    ],\n    \"complexes\": [\"SDC1-TGM2-FLOT1-BHMT complex\"],\n    \"partners\": [\"IGF1R\", \"TGM2\", \"FLOT1\", \"BHMT\", \"SDC4\", \"SDC2\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":7,"faith_pct":85.71428571428571}}